3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
pembrolizumab
5
Nivolumab
3
Cisplatin
3
Taxes
2
Paclitaxel
2
poly ICLC
1
fludarabine phosphate
1
fludarabine
1
abemaciclib
1
Risk Factors
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiation
1
Pemetrexed
1
Nimorazole
1
Injections
1
High-Intensity Focused Ultrasound Ablation
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Biological Products
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
Nimorazole
×
1 year
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled